Malignant Ascites Treatment Market - Size,
Outlook and Opportunity Analysis 2018-2026
Share,
Ascites is the condition characterized by formation of excessive fluid in the abdominal cavity,
particularly in the peritoneal cavity. It causes when the body is unable to eliminate out fluids.
When ascites is developed due to cancer, it is called as malignant peritoneal effusion or
malignant ascites. Malignancies that are most commonly associated with malignant ascites are
cancers of breast, liver, ovary, lungs, lymphoma, and colon. In ascites condition, lymph glands
in the body gets blocked and lead to ascites symptoms including low blood pressure, loss of
sleep, fatigue, and skin problems. Key symptoms in malignant ascites are abdominal pain or
discomfort, shortness of breath, swelling of the abdomen, leg or ankle swelling, constipation,
and weight gain. Diagnosis of ascites can be done by ultrasound, x-ray test, CT scans, and
physical examination. The survival rate of these patients is very low, although with suitable
treatment such as paracentesis, chemotherapy, and surgeries are available. Various conventional
treatment for malignant ascites include chemotherapy, shunting, paracentesis, and use of drugs
such as spironolactone and spironolactone. Cirrhosis of the liver is the most common cause of
ascites but other conditions such as kidney failure, heart failure, cancer or infection can also
cause ascites.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1775
Malignant Ascites Treatment Market – Dynamics
Rising prevalence of cirrhosis is a major factor for growth of the malignant ascites market. For
instance, according to a study published in World Journal of Gastroenterology 2011, over 50%
of patients develop ascites within 10 years diagnosis. According to a published article in Journal
of Clinical and Translational Hepatology 2014 showed advancements in ascites condition is
related with poor prognosis, with a mortality of 15% at one year and 44% at the five year
follow up. Moreover, favorable reimbursement policies like 2010 Patient Protection and
Affordable Care Act (PPACA) and increasing incidence of cancer are also propelling the market
growth. For instance, according to 2018 American Cancer Society report, cancer was responsible